Understanding The Pathophysiology Of Schizophrenia, Major Depressive Disorder And Bipolar Disorder As A Basis For Improving Treatments
Funder
National Health and Medical Research Council
Funding Amount
$804,106.00
Summary
The Applicant seeks to understand the causes of the schizophrenia, bipolar disorder and major depressive disorder, which affect over 20% of the Australian population. This research is important as drug design, based on chemical remodelling, has not significantly advanced initial breakthroughs in treating psychiatric disorders and there is now a widespread belief that new drugs will only come from understand their causes.
Differential Changes In Cortical Tumour Necrosis Factor Signalling In Mood Disorders And Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$642,078.00
Summary
Changes in inflammation-related pathways contribute to the symptoms of psychiatric disorders and tumour necrosis factor ? (TNF) is a protein central to regulating theses pathways. We have now shown that changes in pathways regulated by TNF are present in the brains of people with schizophrenia and mood disorders. This means that the symptoms experienced by those with the different disorders may be linked to differential changes in TNF-regulated pathways in the brain.
PHARMACOGENETICS OF ANTIDEPRESSANT RESPONSE AND REMISSION: TOWARD GENOTYPE-GUIDED PRESCRIBING IN MAJOR DEPRESSIVE DISORDER
Funder
National Health and Medical Research Council
Funding Amount
$435,524.00
Summary
A “one-size fits all” approach to antidepressant pharmacotherapy in depression is suboptimal. Current technology and scientific data support the transition to a personalised approach to antidepressant pharmacotherapy. My research will (1) develop and test genetic based algorithms for their ability to predict antidepressant response and remission and (2) evaluate the clinical validity and utility of currently available algorithms in clinical practice.
Deep Brain Stimulation In The Treatment Of Severe Depression
Funder
National Health and Medical Research Council
Funding Amount
$1,008,087.00
Summary
Some patients with depression fail to respond to a variety of standard treatments and in this group, deep brain stimulation (DBS) is being evaluated as an alternative treatment option. This study will investigate the use of DBS applied to a novel brain target site in patients with highly treatment refractory depression.
Providing Evidence For The Primary Prevention Of The High-prevalence Mental Disorders In Men: The Role Of Diet In The Aetiology Of Depression, Anxiety, And Psychological Distress
Funder
National Health and Medical Research Council
Funding Amount
$300,862.00
Summary
Depression is predicted to become the second-most common cause of disability in the world by 2020, despite the increased energy devoted to recognition and treatment. This study will examine the association between diet quality and depressive and anxiety disorders in men, to identify to what extent diet quality is related to the risk for and/or course of these illnesses.
AusGDB-Depression: An Australian Genetic Database Study Of Functional Genetic Variants And Environmental Factors In Major Depression
Funder
National Health and Medical Research Council
Funding Amount
$620,486.00
Summary
Major depression is the leading cause of disability in Australia, but its causes are unknown. Despite a significant role of genes in this disorder and many genetic studies, researchers have not been able to identify the genes that increase the risk for this disorder. In this project, we will identify, characterize and use genetic functional variants and environmental factors to create a way to predict diagnosis of this disorder.
Predictors Of Response To Antidepressants: Utility Of Behavioural, Neuroimaging And Genetics Data
Funder
National Health and Medical Research Council
Funding Amount
$310,071.00
Summary
Major depressive disorder (MDD) is projected to cause the second greatest global burden of disease by 2020, highlighting the urgent need for valid predictors of effective treatment response. Currently, there are no accurate predictors of response to antidepressants in MDD, and successful treatment relies greatly on 'trial and error'. This process is demanding on health resources, and may be a factor in the high suicide rates in depressed patients. Previous research on treatment response has been ....Major depressive disorder (MDD) is projected to cause the second greatest global burden of disease by 2020, highlighting the urgent need for valid predictors of effective treatment response. Currently, there are no accurate predictors of response to antidepressants in MDD, and successful treatment relies greatly on 'trial and error'. This process is demanding on health resources, and may be a factor in the high suicide rates in depressed patients. Previous research on treatment response has been limited by recruitment of small, heterogeneous patient samples, lack of placebo control, and a failure to examine task related activity in brain imaging studies. Perhaps one of the more troubling aspects of research that aims to predict treatment response to antidepressant medications is the use of commonly used outcome measures such as the Hamilton Rating Depression Scale (HAM-D), which were developed long before current classification systems of depression came into use. The US Federal Drug Administration has recently identified what they call a translational gap such that behavioural and biological measures are the most robust for detection of disorders such as depression, yet these measures remain to be translated into clinical tools that can be used to evaluate treatment. The aim of the current study therefore is to determine whether genetic variability is related to treatment outcome as defined by a more objective outcome measure (facial expression perception) using a randomised controlled design. The study will also determine whether brain measures (fMRI, EEG) enhance the prediction of SSRI response to both clinical and behavioural measures, over and above the genetic contribution.Read moreRead less
Diet As A Therapeutic Target In Depression: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$498,564.00
Summary
Depression is predicted to become the second-most common cause of disability in the world by 2020. While there is now compelling new evidence to suggest that diet plays an important role in the risk for and the genesis of depression, there are no existing data regarding the impact of dietary improvement on existing depressive illness. The aim of the proposed study is to answer the critically important and frequently asked question "If I improve my diet, will my mental health improve?"
Improving Internet-delivered Psychological Therapies For Depression And Anxiety
Funder
National Health and Medical Research Council
Funding Amount
$437,034.00
Summary
Depression and anxiety affect 3 million Australians. While effective psychological treatments exist, even the best only help 50% recover, and relapse is common. My research aims to improve the treatment of adult depression and anxiety, through developing more effective, efficient and accessible internet-delivered psychological therapies and identifying the conditions that promote optimal long-term outcomes.